

# Alessandra Lugaresi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8570938/publications.pdf>

Version: 2024-02-01

245  
papers

10,777  
citations

28190

55  
h-index

46693

89  
g-index

252  
all docs

252  
docs citations

252  
times ranked

7917  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatal Familial Insomnia and Dysautonomia with Selective Degeneration of Thalamic Nuclei. <i>New England Journal of Medicine</i> , 1986, 315, 997-1003.	13.9	688
2	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
3	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281
4	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	4.9	219
5	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. <i>Multiple Sclerosis Journal</i> , 2006, 12, 814-823.	1.4	206
6	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2015, 84, 981-988.	1.5	201
7	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 779-788.	1.4	172
8	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
9	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	2.8	158
10	Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. <i>Neurology</i> , 2001, 57, 62-68.	1.5	156
11	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	1.4	148
12	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	2.8	143
13	Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1208-1214.	1.8	142
14	Pregnancy and fetal outcomes after interferon- $\beta$ exposure in multiple sclerosis. <i>Neurology</i> , 2010, 75, 1794-1802.	1.5	142
15	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	3.7	140
16	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014, 82, 1204-1211.	1.5	138
17	Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011, 77, 145-150.	1.5	135
18	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134

#	ARTICLE	IF	CITATIONS
19	Real-life impact of early interferon $\beta$ therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009, 66, 513-520.	2.8	132
20	Acute motor conduction block neuropathy Another Guillain-Barré syndrome variant. <i>Neurology</i> , 2003, 61, 617-622.	1.5	127
21	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	1.1	122
22	Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 77-87.	1.4	119
23	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012, 18, 835-842.	1.4	115
24	Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. <i>Muscle and Nerve</i> , 1993, 16, 610-615.	1.0	106
25	Anxiety and depression in multiple sclerosis patients around diagnosis. <i>Journal of the Neurological Sciences</i> , 2011, 307, 86-91.	0.3	105
26	The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy. <i>Annals of Neurology</i> , 2004, 56, 631-641.	2.8	102
27	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	4.5	100
28	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014, 14, 171.	0.8	99
29	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94
30	Abnormal brain and muscle energy metabolism shown by $^{31}\text{P}$ -MRS in familial hemiplegic migraine. <i>Journal of the Neurological Sciences</i> , 1995, 129, 214-222.	0.3	82
31	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012, 12, 124.	0.8	82
32	The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. <i>Journal of Neurology</i> , 2002, 249, 152-163.	1.8	81
33	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012, 12, 165.	0.8	78
34	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015, 138, 3275-3286.	3.7	76
35	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137.	0.9	76
36	Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. <i>Journal of Proteomics</i> , 2011, 74, 2826-2836.	1.2	75

#	ARTICLE	IF	CITATIONS
37	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	1.4	73
38	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1225-1233.	1.4	72
39	Patterns of reactivity of human anti-GM1 antibodies with spinal cord and motor neurons. <i>Annals of Neurology</i> , 1992, 32, 487-493.	2.8	71
40	Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?. <i>Clinical Neurophysiology</i> , 2002, 113, 346-353.	0.7	71
41	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
42	Independent component analysis for the extraction of reliable protein signal profiles from MALDI-TOF mass spectra. <i>Bioinformatics</i> , 2008, 24, 63-70.	1.8	70
43	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011, 77, 1887-1895.	1.5	68
44	Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. <i>PLoS ONE</i> , 2014, 9, e109679.	1.1	67
45	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	2.8	67
46	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 845-850.	0.9	66
47	Chronic inflammatory demyelinating polyneuropathy in diabetics: motor conduction are important in the differential diagnosis with diabetic polyneuropathy. <i>Clinical Neurophysiology</i> , 1999, 110, 705-711.	0.7	65
48	Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 995-1002.	2.4	65
49	An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. <i>Molecular BioSystems</i> , 2015, 11, 1563-1572.	2.9	65
50	An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1393-1405.	1.4	64
51	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	0.9	63
52	RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon- $\beta$ . <i>Journal of Neuroimmunology</i> , 2000, 107, 100-107.	1.1	60
53	Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis – Results of the BetaPlus observational cohort study. <i>Journal of the Neurological Sciences</i> , 2011, 307, 120-126.	0.3	59
54	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	0.9	59

#	ARTICLE	IF	CITATIONS
55	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 373-387.	1.7	57
56	Fisher Syndrome with tetraparesis and antibody to GQ1b: Evidence for motor nerve terminal block. , 1999, 22, 640-644.		56
57	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1106-1112.	1.4	56
58	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
59	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1068-1070.	1.4	53
60	Physiological hypnic myoclonus. <i>Electroencephalography and Clinical Neurophysiology</i> , 1988, 70, 172-176.	0.3	52
61	Anti-sulfatide antibodies in neurological disease: binding to rat dorsal root ganglia neurons. <i>Journal of the Neurological Sciences</i> , 1992, 112, 152-159.	0.3	52
62	Idiopathic recurring stupor: A case with possible involvement of the gamma-aminobutyric acid (GABA)ergic system. <i>Annals of Neurology</i> , 1992, 31, 503-506.	2.8	52
63	Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 1029-1042.	1.4	52
64	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52
65	Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. <i>Sleep Medicine</i> , 2019, 56, 90-97.	0.8	51
66	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. <i>Multiple Sclerosis Journal</i> , 2010, 16, 100-111.	1.4	50
67	Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2012, 13, 12656-12664.	1.8	50
68	Patient adherence to and tolerability of self-administered interferon $\beta$ -1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. <i>BMC Neurology</i> , 2012, 12, 7.	0.8	50
69	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	0.9	49
70	Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. <i>BMC Neurology</i> , 2010, 10, 28.	0.8	47
71	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014, 14, 65.	0.8	47
72	Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments. <i>PLoS ONE</i> , 2013, 8, e60721.	1.1	44

#	ARTICLE	IF	CITATIONS
73	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	1.7	43
74	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018, 265, 2851-2860.	1.8	43
75	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1508-1517.	1.4	42
76	Decreased integrin gene expression in patients with MS responding to interferon- $\beta$ treatment. <i>Journal of Neuroimmunology</i> , 2004, 150, 123-131.	1.1	41
77	Pre-analytical factors in clinical proteomics investigations: Impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. <i>Journal of Proteomics</i> , 2010, 73, 579-592.	1.2	41
78	Acute motor axonal neuropathy with high titer IgG and IgA anti-GD1 a antibodies following <i>Campylobacter</i> enteritis. <i>Journal of the Neurological Sciences</i> , 1997, 147, 193-200.	0.3	40
79	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 1094-1098.	1.8	40
80	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016, 23, 33-52.	0.8	39
81	Minimal and asymptomatic chronic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 1999, 110, 694-698.	0.7	38
82	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.5	38
83	Chronic progressive steroid responsive axonal polyneuropathy: A CIDP variant or a primary axonal disorder?. , 1996, 19, 365-371.		37
84	Cleavage of cystatin C is not associated with multiple sclerosis. <i>Annals of Neurology</i> , 2007, 62, 201-204.	2.8	37
85	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310.	0.9	37
86	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. <i>Journal of the Neurological Sciences</i> , 2014, 337, 67-73.	0.3	37
87	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	1.4	37
88	Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone <sup>®</sup> ). <i>Multiple Sclerosis Journal</i> , 2008, 14, 739-748.	1.4	36
89	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	1.4	36
90	Cladribine versus fingolimod, natalizumab and interferon $\beta$ for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.	1.4	36

#	ARTICLE	IF	CITATIONS
91	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.3	35
92	Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 663-674.	1.4	35
93	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	0.9	35
94	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	1.1	35
95	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
96	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	2.8	34
97	Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , 1999, 95, 190-194.	1.1	33
98	Comparative efficacy of first-line natalizumab vs IFN- $\beta$ or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	0.8	33
99	<sc>BREMSO</sc>: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 981-989.	1.7	32
100	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
101	â€Psychic Akinesiaâ€™ following Carbon Monoxide Poisoning. <i>European Neurology</i> , 1990, 30, 167-169.	0.6	31
102	Anti-GD1a antibodies from an acute motor axonal neuropathy patient selectively bind to motor nerve fiber nodes of Ranvier. <i>Journal of Neuroimmunology</i> , 2001, 121, 79-82.	1.1	31
103	Hand dystonia secondary to cervical demyelinating lesion. <i>Acta Neurologica Scandinavica</i> , 1994, 90, 51-55.	1.0	31
104	A computational platform for MALDI-TOF mass spectrometry data: Application to serum and plasma samples. <i>Journal of Proteomics</i> , 2010, 73, 562-570.	1.2	31
105	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015, 15, 204.	0.8	31
106	Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations. <i>PLoS ONE</i> , 2015, 10, e0127734.	1.1	31
107	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. <i>PLoS ONE</i> , 2016, 11, e0153466.	1.1	31
108	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	31

#	ARTICLE	IF	CITATIONS
109	Extrapyramidal Syndrome and Depression Induced by Flunarizine. <i>European Neurology</i> , 1988, 28, 208-211.	0.6	30
110	Effect of rhTNF- $\alpha$ injection into rat sciatic nerve. <i>Journal of Neuroimmunology</i> , 1999, 94, 88-94.	1.1	30
111	<b>RebiSmart <sup>®</sup> , <sup>®</sup> (version 1.5) device for multiple sclerosis treatment delivery and adherence</b>. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 273-283.	2.4	30
112	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014, 35, 307-316.	0.9	30
113	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	1.4	30
114	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. <i>Frontiers in Psychology</i> , 2017, 8, 2216.	1.1	30
115	LACK OF VEGETATIVE AND ENDOCRINE ORCADIAN RHYTHMS IN FATAL FAMILIAL THALAMIC DEGENERATION. <i>Clinical Endocrinology</i> , 1987, 26, 573-580.	1.2	29
116	IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. <i>Experimental Gerontology</i> , 2004, 39, 653-657.	1.2	29
117	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1355-1359.	0.9	29
118	Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. <i>Journal of Neurology</i> , 2013, 260, 1583-1593.	1.8	29
119	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	0.9	29
120	Benign monomelic amyotrophy of lower limb: a rare entity with a characteristic muscular CT. <i>Journal of the Neurological Sciences</i> , 1994, 126, 153-161.	0.3	28
121	Lymphomononuclear cells from multiple sclerosis patients spontaneously produce high levels of oncostatin M, tumor necrosis factors $\alpha$ 1 and $\alpha$ 2, and interferon $\gamma$ . <i>Multiple Sclerosis Journal</i> , 2002, 8, 284-288.	1.4	28
122	Protein profiling of Guillain-Barré syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry. <i>Neuroscience Letters</i> , 2010, 485, 49-54.	1.0	28
123	Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 893.	1.0	28
124	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 184.	0.7	28
125	How many injections did you miss last month? A simple question to predict interferon $\beta$ -1a adherence in multiple sclerosis. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1829-1835.	2.4	28
126	Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1237-1247.	1.4	27



#	ARTICLE	IF	CITATIONS
127	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014, 14, 114.	0.8	27
128	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1297-1303.	0.9	27
129	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	1.1	26
130	Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 366, 139-145.	0.3	26
131	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	4.5	26
132	Effect of oxygen radicals and hyperoxia on rat heart ornithine decarboxylase activity. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1982, 718, 157-164.	1.1	25
133	Interferon $\beta$ -1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 123, 170-179.	1.1	25
134	Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period. <i>Clinical Neuropharmacology</i> , 2008, 31, 167-172.	0.2	25
135	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , 2017, 38, 53-59.	0.9	25
136	Sleep Apneas, Convulsive Syncope and Autonomic Impairment in Type I Arnold-Chiari Malformation. <i>European Neurology</i> , 1991, 31, 36-40.	0.6	24
137	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
138	Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. <i>Neurological Sciences</i> , 2001, 22, 209-210.	0.9	23
139	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009, 286, 109-113.	0.3	23
140	Natalizumab Treatment in Multiple Sclerosis Patients: A Multicenter Experience in Clinical Practice in Italy. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 147-154.	1.0	23
141	Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. <i>Journal of Neuroinflammation</i> , 2015, 12, 146.	3.1	23
142	The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. <i>Neurological Sciences</i> , 2011, 32, 1035-1041.	0.9	22
143	Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis. <i>Proteomics</i> , 2013, 13, 1002-1009.	1.3	22
144	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 105-108.	0.9	22

#	ARTICLE	IF	CITATIONS
145	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.	0.3	22
146	Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 261-267.	0.9	22
147	Identification of glycoconjugates which are targets for anti-Gal(β1-3)GalNAc autoantibodies in spinal motor neurons. <i>Journal of Neuroimmunology</i> , 1991, 34, 69-76.	1.1	21
148	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 729-736.	1.7	21
149	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019, 10, 916.	1.1	21
150	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	4.5	21
151	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013, 34, 1633-1637.	0.9	20
152	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	4.5	20
153	Interferon beta normalizes suppressor cell function in dysimmune neuropathies. <i>Journal of Neuroimmunology</i> , 1998, 82, 1-4.	1.1	19
154	Improving patient&ndash;physician dialog: commentary on the results of the MS Choices survey. <i>Patient Preference and Adherence</i> , 2012, 6, 143.	0.8	19
155	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	1.4	19
156	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	1.4	18
157	Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. <i>Frontiers in Neurology</i> , 2021, 12, 554375.	1.1	18
158	Isolated Bovine Spinal Motoneurons Have Specific Ganglioside Antigens Recognized by Sera from Patients with Motor Neuron Disease and Motor Neuropathy. <i>Journal of Neurochemistry</i> , 1992, 59, 1684-1691.	2.1	17
159	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , 2005, 26, s200-s203.	0.9	17
160	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group&#x2014;Italian Neurological Society. <i>Neurological Sciences</i> , 2011, 32, 351-358.	0.9	17
161	Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study. <i>International Journal of Clinical Practice</i> , 2012, 66, 504-514.	0.8	17
162	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	0.9	17

#	ARTICLE	IF	CITATIONS
163	Fasciculations during wakefulness and sleep. <i>Acta Neurologica Scandinavica</i> , 1987, 76, 152-154.	1.0	16
164	Basal ganglia involvement in multiple sclerosis with alternating side paroxysmal dystonia. <i>Journal of Neurology</i> , 1993, 240, 257-261.	1.8	16
165	Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon $\beta$ -1a using an electronic device: the RIVER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 931-935.	2.4	16
166	Severe dysautonomic onset of Guillain-Barré syndrome with good recovery. A clinical and autonomic follow-up study. <i>Italian Journal of Neurological Sciences</i> , 1990, 11, 157-162.	0.1	15
167	Ponesimod for the treatment of relapsing multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1955-1964.	0.9	15
168	Steroid-responsive multifocal demyelinating neuropathy with central involvement. , 1999, 22, 262-265.		14
169	Implementation of the "Sapere Migliora"™ information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1234-1243.	1.4	14
170	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. <i>Neurological Sciences</i> , 2016, 37, 613-622.	0.9	14
171	Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. <i>Journal of the Neurological Sciences</i> , 2005, 237, 5-11.	0.3	13
172	First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. <i>Current Medical Research and Opinion</i> , 2018, 34, 1803-1807.	0.9	13
173	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479.	1.4	13
174	Diurnal variability in cranial dystonia. <i>Movement Disorders</i> , 1990, 5, 44-46.	2.2	12
175	Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS trial. <i>Health Expectations</i> , 2014, 17, 36-48.	1.1	12
176	Circadian Activity Rhythm in Early Relapsing-Remitting Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 2216.	1.0	12
177	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	1.7	12
178	The impact of the COVID-19 pandemic on people with neurological disorders: an urgent need to enhance the health care systems preparedness. <i>Neurological Sciences</i> , 2021, 42, 799-804.	0.9	12
179	Advance Care Planning in Neurodegenerative Disorders: A Scoping Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 803.	1.2	12
180	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	12

#	ARTICLE	IF	CITATIONS
181	Sympathetic skin response in hemispheric lesions. <i>Neurophysiologie Clinique</i> , 1992, 22, 475-481.	1.0	11
182	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. <i>Multiple Sclerosis Journal</i> , 2019, 25, 856-866.	1.4	11
183	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	1.4	11
184	Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31. <i>Neurological Sciences</i> , 2021, 42, 1395-1403.	0.9	11
185	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2022, 29, 1082-1090.	1.7	11
186	Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. <i>Journal of Translational Medicine</i> , 2011, 9, 42.	1.8	10
187	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. <i>Quality of Life Research</i> , 2016, 25, 2755-2763.	1.5	10
188	Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure. <i>Health Expectations</i> , 2016, 19, 437-447.	1.1	10
189	Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?. <i>Journal of the Neurological Sciences</i> , 2017, 378, 233-237.	0.3	10
190	Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. <i>Clinical Neuropharmacology</i> , 2018, 41, 171-176.	0.2	10
191	Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis. <i>Neurological Sciences</i> , 2019, 40, 75-80.	0.9	10
192	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1765-1774.	1.4	10
193	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	1.8	10
194	Autonomic nervous system function in myotonic dystrophy. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 589-592.	0.1	9
195	Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. <i>Journal of Neurology</i> , 2013, 260, 1258-1262.	1.8	9
196	Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0200532.	1.1	9
197	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.3	9
198	Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 295-306.	1.5	8

#	ARTICLE	IF	CITATIONS
199	“Nail loss after teriflunomide treatment: A new potential adverse event” Multiple Sclerosis and Related Disorders, 2017, 18, 170-172.	0.9	8
200	Arthritic psoriasis during natalizumab treatment: a case report and review of the literature. Neurological Sciences, 2018, 39, 181-183.	0.9	8
201	Silent lesions on MRI imaging “ Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	1.4	8
202	The effectiveness of natalizumab vs fingolimod “A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	0.9	8
203	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	2.7	8
204	HTLV-1-associated myeloneuropathy in an Italian. Acta Neurologica Scandinavica, 1991, 84, 186-191.	1.0	7
205	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	1.4	7
206	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
207	Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240.	0.9	6
208	Detection of disability worsening in relapsing remitting multiple sclerosis patients: a real world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	1.7	6
209	Distal myasthenia gravis and sensory neuronopathy with anti-50 kDa antibody mimicking sensory-motor neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 414-414.	0.9	6
210	Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , .	2.8	6
211	The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study. Multiple Sclerosis Journal, 2022, 28, 1364-1372.	1.4	6
212	Fatal Familial Insomnia and Dysautonomia. New England Journal of Medicine, 1987, 316, 1027-1028.	13.9	5
213	Amplifications of multiple regions of the HTLV-1 genome from DNA of an Italian spastic paraparesis patient but not from DNA of multiple sclerosis patients. Journal of the Neurological Sciences, 1991, 103, 82-89.	0.3	5
214	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731560019.	0.5	5
215	Teeth loss after teriflunomide treatment: Casual or causal? A short case series. Multiple Sclerosis and Related Disorders, 2018, 24, 120-122.	0.9	5
216	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. PLoS ONE, 2016, 11, e0157721.	1.1	5

#	ARTICLE	IF	CITATIONS
217	Inflammatory optic neuropathy following SARS-CoV-2 mRNA vaccine: Description of two cases. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118186.	0.3	5
218	Isolated failure of noradrenergic transmission in a case with orthostatic hypotension and hyperactivity of gastro-colic reflex. <i>Clinical Autonomic Research</i> , 1992, 2, 177-182.	1.4	4
219	Demyelinating motor Guillain-Barré syndrome following rubella. <i>Neurology</i> , 2005, 64, 390-390.	1.5	4
220	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	4
221	Assessing measurement invariance of MSQOL-54 across Italian and English versions. <i>Quality of Life Research</i> , 2020, 29, 783-791.	1.5	4
222	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. <i>Neuroepidemiology</i> , 2021, 55, 224-231.	1.1	4
223	Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial. <i>BMJ Open</i> , 2021, 11, e052012.	0.8	4
224	F response in vascular and degenerative upper motor neuron lesions. <i>Neurophysiologie Clinique</i> , 1990, 20, 259-268.	1.0	3
225	Letters to the editor. <i>Muscle and Nerve</i> , 1996, 19, 1636-1642.	1.0	3
226	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3
227	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	1.7	3
228	Recurrent cranial nerve palsies, midbrain infarction and hydrocephalus due to megadolichobasilar artery. <i>Italian Journal of Neurological Sciences</i> , 1990, 11, 487-492.	0.1	2
229	Mononeuropathy following subcutaneous interferon- $\beta$ injection. <i>Journal of Neurology</i> , 2006, 253, 961-962.	1.8	2
230	Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1309-1320.	0.9	2
231	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 224.	1.0	2
232	Cannabis-Based Products in a Neurological Setting: A Clinical and Pharmacokinetic Survey. <i>Frontiers in Neurology</i> , 2022, 13, 784748.	1.1	2
233	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	1.4	2
234	Transdermal scopolamine cycloplegia in juvenile diabetes. <i>Italian Journal of Neurological Sciences</i> , 1989, 10, 203-205.	0.1	1

#	ARTICLE	IF	CITATIONS
235	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117064.	0.3	1
236	Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 269-277.	1.7	1
237	Autonomic failure in a case of Chiari malformation type I. <i>Functional Neurology</i> , 1987, 2, 511-3.	1.3	1
238	Effect of Natalizumab treatment on circulating CD4+ CD62L+ T-cells in Multiple Sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014, 275, 137.	1.1	0
239	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [ <i>Mult. Scler. Relat. Disord.</i> (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 166.	0.9	0
240	PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET. <i>Value in Health</i> , 2018, 21, S332.	0.1	0
241	A Pilot Study of 24-h Motor Activity Patterns in Multiple Sclerosis: Pre-Planned Follow-Up at 2 Years. <i>Clocks &amp; Sleep</i> , 2021, 3, 366-376.	0.9	0
242	Balance disorders in multiple sclerosis: The use of postural test in functional clinical assessment. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118187.	0.3	0
243	Long-term disability progression in childhood and adolescent onset multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117747.	0.3	0
244	Construction of a resource for advance care planning in multiple sclerosis (ConCure-SM): Results of cognitive debriefing with users. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118081.	0.3	0
245	Progression independent of relapse activity in early multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117771.	0.3	0